Citation | Caldwell, RD; Qiu, H; Askew, BC; Bender, AT; Brugger, N; Camps, M; Dhanabal, M; Dutt, V; Eichhorn, T; Gardberg, AS; Goutopoulos, A; Grenningloh, R; Head, J; Healey, B; Hodous, BL; Huck, BR; Johnson, TL; Jones, C; Jones, RC; Mochalkin, I; Morandi, F; Nguyen, N; Meyring, M; Potnick, JR; Santos, DC; Schmidt, R; Sherer, B; Shutes, A; Urbahns, K; Follis, AV; Wegener, AA; Zimmerli, SC; Liu-Bujalski, L Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem62:7643-7655 (2019) [PubMed] Article |
---|
SMILES | Nc1ncnc(N[C@@H]2CC[C@@H](CC2)NC(=O)C=C)c1-c1ccc(Oc2ccccc2)cc1 |r,wU:7.6,10.13,(.67,-5.78,;-.67,-5,;-2,-5.78,;-3.33,-5,;-3.33,-3.47,;-2,-2.69,;-2,-1.15,;-3.33,-.38,;-3.33,1.15,;-4.67,1.93,;-6,1.15,;-6,-.38,;-4.67,-1.15,;-7.34,1.93,;-7.34,3.47,;-6,4.23,;-8.67,4.23,;-8.67,5.78,;-.67,-3.47,;.67,-2.69,;2,-3.47,;3.33,-2.69,;3.33,-1.15,;4.67,-.38,;6,-1.15,;6,-2.69,;7.34,-3.47,;8.67,-2.69,;8.67,-1.15,;7.34,-.38,;2,-.38,;.67,-1.15,)| |